4//SEC Filing
FLEMING JONATHAN 4
Accession 0001104659-11-030379
CIK 0001428522other
Filed
May 18, 8:00 PM ET
Accepted
May 19, 9:46 PM ET
Size
18.3 KB
Accession
0001104659-11-030379
Insider Transaction Report
Form 4
FLEMING JONATHAN
Director
Transactions
- Award
Series A-2 Convertible Preferred Stock
2011-05-17+108,628→ 108,628 total(indirect: By Fund)From: 2011-05-17→ Common Stock (1,086,280 underlying) - Award
Common Stock
2011-05-17+15,173→ 15,173 total(indirect: By fund) - Award
Common Stock
2011-05-17+151→ 15,324 total(indirect: By fund) - Award
Series A-2 Convertible Preferred Stock
2011-05-17+1,090→ 109,718 total(indirect: By Fund)From: 2011-05-17→ Common Stock (10,900 underlying) - Award
Series A-3 Convertible Preferred Stock
2011-05-17+250→ 25,233 total(indirect: By Fund)From: 2011-05-17→ Common Stock (2,500 underlying) - Award
Series A-3 Convertible Preferred Stock
2011-05-17+24,983→ 24,983 total(indirect: By Fund)From: 2011-05-17→ Common Stock (249,830 underlying)
Footnotes (10)
- [F1]Received in exchange for 15,173 shares of common stock of Radius Health, Inc. in connection with the merger of RHI Merger Corp., a wholly-owned subsidiary of the Registrant (f/k/a MPM Acquisition Corp.), with and into Radius Health, Inc. ("Target") pursuant to which Target survived and became a wholly-owned subsidiary of Registrant (the "Surviving Corporation"). Following such merger, the Surviving Corporation merged with and into its parent corporation, the Registrant, and subsequently changed its name to "Radius Health, Inc." (the "Merger").
- [F10]Received in exchange for 2,500 shares of Series A-3 convertible preferred stock of Radius Health, Inc. in connection with the Merger.
- [F2]The reported securities are owned directly by OBP IV - Holdings LLC ("OBP IV") and indirectly by Oxford Bioscience Partners IV L.P. ("OBP LP"), a member of OBP IV, and OBP Management IV L.P. ("OBP Management IV"), the sole general partner of OBP LP. Jonathan Fleming is one of two individual general partners of OBP Management IV. Mr. Fleming disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
- [F3]Received in exchange for 151 shares of common stock of Radius Health, Inc. in connection with the Merger.
- [F4]The reported securities are owned directly by mRNA II - Holdings LLC ("mRNA II") and indirectly by mRNA Fund II ("mRNA LP"), a member of mRNA II, and OBP Management IV L.P. ("OBP Management IV"), the sole general partner of mRNA LP. Jonathan Fleming is one of two individual general partners of OBP Management IV. Mr. Fleming disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
- [F5]The Series A-2 convertible preferred stock is convertible into common stock at any time on a one-for-ten basis, and has no expiration date.
- [F6]Received in exchange for 1,086,280 shares of Series A-2 convertible preferred stock of Radius Health, Inc. in connection with the Merger.
- [F7]Received in exchange for 10,900 shares of Series A-2 convertible preferred stock of Radius Health, Inc. in connection with the Merger.
- [F8]The Series A-3 convertible preferred stock is convertible into common stock at any time on a one-for-ten basis, and has no expiration date.
- [F9]Received in exchange for 249,830 shares of Series A-3 convertible preferred stock of Radius Health, Inc. in connection with the Merger.
Documents
Issuer
Radius Health, Inc.
CIK 0001428522
Entity typeother
Related Parties
1- filerCIK 0001262294
Filing Metadata
- Form type
- 4
- Filed
- May 18, 8:00 PM ET
- Accepted
- May 19, 9:46 PM ET
- Size
- 18.3 KB